Brief: Dicot Broadens The Testing Of The Drug Candidate LIB-01 Conducts Studies Of Premature Ejaculation

Dicot Pharma AB

05/02/2021 09:15

Feb 5 (Reuters) - Dicot AB  DICOT.TE :
    * DICOT BROADENS THE TESTING OF THE DRUG CANDIDATE LIB-01:
CONDUCTS STUDIES OF PREMATURE EJACULATION
    * GOAL FOR ITS DRUG CANDIDATE LIB-01 (FORMERLY LIBIGUIN) IS
TO BE
LEADING TREATMENT FOR ERECTILE DYSFUNCTION AND PREMATURE
EJACULATION
    * TESTING IS NOW BEING EXTENDED BY INCLUDING PREMATURE
EJACULATION
TO ASSESS EFFECT OF DRUG CANDIDATE IN ANIMAL MODELS RELEVANT TO
THIS INDICATION
    * RESULTS ARE EXPECTED TO BE ANNOUNCED LATER IN 2021

Source text for Eikon:  ID:nWkr5BkHSR 
Further company coverage:  DICOT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))